Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer.
Aristu JJ, Arbea L, Rodriguez J, Hernández-Lizoain JL, Sola JJ, Moreno M, Azcona JD, Díaz-González JA, García-Foncillas JM, Martínez-Monge R. Aristu JJ, et al. Among authors: moreno m. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):748-55. doi: 10.1016/j.ijrobp.2007.10.023. Epub 2007 Dec 31. Int J Radiat Oncol Biol Phys. 2008. PMID: 18164861 Clinical Trial.
Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
Valero J, Cambeiro M, Galán C, Teijeira M, Romero P, Zudaire J, Moreno M, Ciérvide R, Aristu JJ, Martínez-Monge R. Valero J, et al. Among authors: moreno m. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):386-92. doi: 10.1016/j.ijrobp.2009.01.059. Epub 2009 May 8. Int J Radiat Oncol Biol Phys. 2010. PMID: 19427741 Clinical Trial.
Patterns of response after preoperative intensity-modulated radiation therapy and capecitabine/oxaliplatin in rectal cancer: is there still a place for ecoendoscopic ultrasound?
Arbea L, Díaz-González JA, Subtil JC, Sola J, Hernandez-Lizoain JL, Martínez-Monge R, Moreno M, Aristu J. Arbea L, et al. Among authors: moreno m. Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):439-44. doi: 10.1016/j.ijrobp.2010.05.028. Epub 2010 Aug 26. Int J Radiat Oncol Biol Phys. 2011. PMID: 20800389
Determinants of complications and outcome in high-risk squamous cell head-and-neck cancer treated with perioperative high-dose rate brachytherapy (PHDRB).
Martínez-Monge R, Pagola Divassón M, Cambeiro M, Gaztañaga M, Moreno M, Arbea L, Montesdeoca N, Alcalde J. Martínez-Monge R, et al. Among authors: moreno m. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e245-54. doi: 10.1016/j.ijrobp.2011.03.026. Epub 2011 May 27. Int J Radiat Oncol Biol Phys. 2011. PMID: 21620582
Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L, Martínez-Monge R, Díaz-González JA, Moreno M, Rodríguez J, Hernández JL, Sola JJ, Ramos LI, Subtil JC, Nuñez J, Chopitea A, Cambeiro M, Gaztañaga M, García-Foncillas J, Aristu J. Arbea L, et al. Among authors: moreno m. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):587-93. doi: 10.1016/j.ijrobp.2011.06.2008. Epub 2011 Nov 11. Int J Radiat Oncol Biol Phys. 2012. PMID: 22079731 Clinical Trial.
External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
Martínez-Monge R, Moreno M, Ciérvide R, Cambeiro M, Pérez-Gracia JL, Gil-Bazo I, Gaztañaga M, Arbea L, Pascual I, Aristu J. Martínez-Monge R, et al. Among authors: moreno m. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e469-76. doi: 10.1016/j.ijrobp.2011.08.002. Int J Radiat Oncol Biol Phys. 2012. PMID: 22284039 Clinical Trial.
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Nieto Y, Aramendía JM, Espinós J, De la Cruz S, Fernández-Hidalgo O, Santisteban M, Arbea L, Aristu J, Martínez-Monge R, Moreno M, Pina L, Sola J, Zornoza G, Regueira FM. Nieto Y, et al. Among authors: moreno m. Cancer Chemother Pharmacol. 2010 Feb;65(3):457-65. doi: 10.1007/s00280-009-1049-y. Epub 2009 Jun 14. Cancer Chemother Pharmacol. 2010. PMID: 19526361 Free PMC article. Clinical Trial.
3,353 results